BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+23.73%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$8.79B
AUM Growth
+$8.79B
(-49%)
Cap. Flow
-$9.7B
Cap. Flow
% of AUM
-110.42%
Top 10 Holdings %
Top 10 Hldgs %
80.97%
Holding
105
New
4
Increased
23
Reduced
13
Closed
21
Top Buys
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$159M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$98.3M |
| 3 |
Revolution Medicines
RVMD
|
$70.5M |
| 4 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$67.8M |
| 5 |
Replimune Group
REPL
|
$41.9M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$9.45B |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$337M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$198M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
$69.4M |
| 5 |
Roivant Sciences
ROIV
|
$48.1M |
Sector Composition
| 1 | Healthcare | 98.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Nurix Therapeutics
NRIX
$723M
| $40.1M | 0.46% |
3,882,125
| – | – |
|
|
JBIO
27
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $38M | 0.43% |
1,680,517
-282,962
| -14% | -$6.4M |
|
28
IDEAYA Biosciences
IDYA
$2.26B
| $37.8M | 0.43% |
1,062,123
| – | – |
|
29
Edgewise Therapeutics
EWTX
$1.54B
| $34.1M | 0.39% |
3,112,786
+2,063,087
| +197% | +$22.6M |
|
30
Sera Prognostics
SERA
$129M
| $32.5M | 0.37% |
5,434,399
+3,919,057
| +259% | +$23.4M |
|
|
BCYC
31
Bicycle Therapeutics
BCYC
$492M
| $32.4M | 0.37% |
1,790,390
+946,576
| +112% | +$17.1M |
|
|
IGMS
32
DELISTED
IGM Biosciences
IGMS
| $30.7M | 0.35% |
3,691,011
+533,247
| +17% | +$4.43M |
|
33
Biomea Fusion
BMEA
$114M
| $30.6M | 0.35% |
2,108,949
| – | – |
|
34
Monte Rosa Therapeutics
GLUE
$309M
| $27.8M | 0.32% |
4,916,095
| – | – |
|
|
VERV
35
DELISTED
Verve Therapeutics
VERV
| $23.6M | 0.27% |
1,691,530
+275,000
| +19% | +$3.83M |
|
36
Krystal Biotech
KRYS
$4.35B
| $21.1M | 0.24% |
169,934
| – | – |
|
|
GRCL
37
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $20.9M | 0.24% |
2,080,000
+1,080,000
| +108% | +$10.8M |
|
38
Immunovant
IMVT
$2.91B
| $17.9M | 0.2% |
425,009
| – | – |
|
39
TScan Therapeutics
TCRX
$106M
| $16.2M | 0.18% |
2,784,792
| – | – |
|
40
Day One Biopharmaceuticals
DAWN
$766M
| $14.6M | 0.17% |
1,000,000
| – | – |
|
|
DBVT
41
DBV Technologies
DBVT
$249M
| $13.9M | 0.16% |
14,614,264
| – | – |
|
42
Relay Therapeutics
RLAY
$709M
| $12.8M | 0.15% |
1,160,117
| – | – |
|
43
ARS Pharmaceuticals
SPRY
$1.08B
| $11M | 0.13% |
2,006,451
| – | – |
|
44
Stoke Therapeutics
STOK
$1.08B
| $10.7M | 0.12% |
2,030,134
+544,219
| +37% | +$2.86M |
|
|
TSVT
45
DELISTED
2seventy bio
TSVT
| $10.7M | 0.12% |
2,497,526
| – | – |
|
46
Insmed
INSM
$30.3B
| $10.6M | 0.12% |
343,000
| – | – |
|
47
Celldex Therapeutics
CLDX
$1.57B
| $9.82M | 0.11% |
+247,644
| New | +$9.82M |
|
48
Prime Medicine
PRME
$595M
| $9.11M | 0.1% |
1,028,466
| – | – |
|
49
Neurogene
NGNE
$284M
| $8.79M | 0.1% |
453,516
-767,898
| -63% | +$2.87M |
|
|
ADAP
50
Adaptimmune Therapeutics
ADAP
$13.9M
| $8.7M | 0.1% |
10,969,282
| – | – |
|